↓ Skip to main content

Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults

Overview of attention for article published in Vaccine, August 2022
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#1 of 16,611)
  • High Attention Score compared to outputs of the same age (99th percentile)
  • High Attention Score compared to outputs of the same age and source (99th percentile)

Citations

dimensions_citation
98 Dimensions

Readers on

mendeley
231 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults
Published in
Vaccine, August 2022
DOI 10.1016/j.vaccine.2022.08.036
Pubmed ID
Authors

Joseph Fraiman, Juan Erviti, Mark Jones, Sander Greenland, Patrick Whelan, Robert M Kaplan, Peter Doshi

X Demographics

X Demographics

The data shown below were collected from the profiles of 33,780 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 231 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 231 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 27 12%
Other 21 9%
Student > Ph. D. Student 17 7%
Student > Bachelor 12 5%
Student > Postgraduate 11 5%
Other 33 14%
Unknown 110 48%
Readers by discipline Count As %
Medicine and Dentistry 41 18%
Biochemistry, Genetics and Molecular Biology 18 8%
Nursing and Health Professions 7 3%
Immunology and Microbiology 7 3%
Pharmacology, Toxicology and Pharmaceutical Science 6 3%
Other 32 14%
Unknown 120 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 17845. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 April 2024.
All research outputs
#43
of 25,736,439 outputs
Outputs from Vaccine
#1
of 16,611 outputs
Outputs of similar age
#1
of 431,420 outputs
Outputs of similar age from Vaccine
#1
of 172 outputs
Altmetric has tracked 25,736,439 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 99th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,611 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.9. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 431,420 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 99% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.